Advertisement

Topics

Monoclonal antibody prevents graft-vs-host disease in bone marrow transplantation model

19:00 EST 13 Nov 2017 | AAAS

(Bioscribe) New research provides preclinical proof-of-concept for the ability of PRO 140, a humanized anti-CCR5 monoclonal antibody under development by CytoDyn Inc., to effectively block the development of graft-versus-host disease, a potentially lethal complication of bone marrow stem cell transplantation. CytoDyn is currently enrolling patients in a Phase 2 clinical trial with PRO 140 for the prevention of GvHD in leukemia patients undergoing BMSC transplantation.

Original Article: Monoclonal antibody prevents graft-vs-host disease in bone marrow transplantation model

NEXT ARTICLE

More From BioPortfolio on "Monoclonal antibody prevents graft-vs-host disease in bone marrow transplantation model"

Quick Search
Advertisement
 

Relevant Topics

Antibodies
An antibody is a protein produced by the body's immune system when it detects harmful substances, called antigens. Examples of antigens include microorganisms (such as bacteria, fungi, parasites, and viruses) and chemicals. Antibodies may be produc...

Osteoporosis
Osteoporosis is a disease in which the bones become extremely porous, are subject to fracture, and heal slowly, occurring especially in women following menopause and often leading to curvature of the spine from vertebral collapse. Follow and track&n...

Stem Cells
Track and monitor developments in stem cell research and commercial development.  Follow the tabs above to read the latest global news, research, clinical trials on stem cells and follow companies active in the stem cell industry.  BioPort...